Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab-Reference-Cited by-同舟云学术

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab

Published:2018-02-13 Issue:4 Volume:23 Page:634-640
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nakaya Aya^ORCID,Kurata Takayasu,Yoshioka Hiroshige,Takeyasu Yuki,Niki Maiko,Kibata Kayoko,Satsutani Naoko,Ogata Makoto,Miyara Takayuki,Nomura Shosaku

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-018-1250-2/fulltext.html

Reference31 articles.

1. Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

2. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

3. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

4. Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:124. https://doi.org/10.1093/jnci/dju124

5. Luo G, Guo M, Liu Z et al (2015) Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol 22:670–676

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy;Human Vaccines & Immunotherapeutics;2024-09-13

2. Immune‐inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer receiving first‐line immunotherapy;Thoracic Cancer;2024-08-27

3. Prognostic and clinicopathological value of systemic immune-inflammation index in patients with osteosarcoma: a meta-analysis;Frontiers in Immunology;2024-08-15

4. Efficacy and safety of maintenance therapy with anlotinib for advanced cholangiocarcinoma after first-line chemotherapy and the variations in efficacy based on different neutrophil-to-lymphocyte ratio (NLR);World Journal of Surgical Oncology;2024-07-29

5. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG);European Archives of Oto-Rhino-Laryngology;2024-05-25